LEADERSHIP
NAB has gathered a world class management team with extensive expertise and a successful track record in drug development, commercialization, and asset management of cancer immunotherapies (monotherapy as well as combinations and ADCs), reformulation, and orphan drug development. All our C- Suite leaders have medical training, and leaders in their respective departments. The entire leadership of NAB are industry seasoned females, MDs, and of the highest professional caliber in their class. An all-female, private company, with no current debt, owns its robust IP with the proven track record in human trials, with the support of the opinion leaders of the respective therapeutic areas. A value driven organization with serving the patients as its only mission.
Timothy Allen, MD, Ph.D.(EVP, R&D- Clinical Development Strategy)
An individual contributor to Medical in developing and performing all aspects of Clinical Development, IND thru NDA/BLA, more than 20 years in asset management. Leading health authority meetings; types C included, and mentoring cross functional team including the clinical team, pre- clinical translational, etc. in measuring into pivotal trials, submissions and post submissions activities. Grew from a medical monitor, into asset lead, and department head. Specifics are available upon a mutual confidential disclosure agreement (CDA).My clinical development history included successful IND, NDA and BLAs at Merck/SPC, Celgene, BMS, GSK, BI, AZ, as well as Roche/Genentech. Published articles and textbooks:
Ghazaleh Shoja E Razavi, MD (Chief Medical Officer)
Ghazaleh is a practicing hematologist, medical oncologist with more than ten years of clinical experience. She also has a deep knowledge and understanding of pharmaceutical environment with more than five years industry experience in safety, pharmacovigilance, medical affairs as well as designing and monitoring of clinical trials in active immunotherapy, immune-oncology and novel chemo and targeted anti-cancer agents. She has been graduated from medical school in 1997, board certified in internal medicine in 2002 and board certified in hematology and medical oncology in 2006. She has also trained in supportive and palliative care in Italy, granted by European Society for Medical Oncology (ESMO) in 2007 and completed her clinical fellowship in malignant hematology and stem cell transplant in Canada in 2017.